TCGA-A8-A09W-01A-11R-A00Z-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 1
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.550
- G2M_CHECKPOINT+0.500
- MYC_TARGETS_V1+0.460
- MTORC1_SIGNALING+0.450
- OXIDATIVE_PHOSPHORYLATION+0.440
- ANDROGEN_RESPONSE+0.400
- PROTEIN_SECRETION+0.390
- FATTY_ACID_METABOLISM+0.370
- ADIPOGENESIS+0.320
- CHOLESTEROL_HOMEOSTASIS+0.320
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.340
- TNFA_SIGNALING_VIA_NFKB-0.330
- APICAL_SURFACE-0.250
- WNT_BETA_CATENIN_SIGNALING-0.230
- MYOGENESIS-0.210
- KRAS_SIGNALING_DN-0.160
- TGF_BETA_SIGNALING-0.160
- NOTCH_SIGNALING-0.150
- APICAL_JUNCTION-0.120
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12475163 | — | — | 0.871 |
| 2 | TCGA-66-2727-01A-01R-0980-07 | — | cohortSQ2 | 0.862 |
| 3 | 77984740-019e-482f-822a-25a74ec2cc32 | — | — | 0.847 |
| 4 | 8824c0fd-764e-4525-952b-f25efa742772 | — | — | 0.846 |
| 5 | SJEPD030169_D1.RNA-Seq | EPN | EPN Tumor | 0.840 |
| 6 | 0e1c98de-b4e2-4f42-beca-9948f867a46b | — | — | 0.837 |
| 7 | c7aea5a2-5772-4475-8ca6-326193eeb69e | — | — | 0.834 |
| 8 | TCGA-95-7562-01A-11R-2241-07 | — | cohortA4 | 0.829 |
| 9 | BS_TXZ7KHTQ | high-grade glioma | — | 0.823 |
| 10 | 3fca0833-b19b-47af-b75e-c9c45a99373b | — | — | 0.823 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.550 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.460 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.450 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.440 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.400 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.390 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.370 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.320 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.320 | Remibrutinib | — uncovered |
| PEROXISOME | 0.320 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.320 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.290 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.250 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.250 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.240 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.190 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.190 | Temsirolimus | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.190 | Idelalisib | — uncovered |